52 min ago
BioMarin Pharmaceutical (BMRN) Posts Quarterly Earnings, Beats Estimates By $0.18 EPS
BioMarin Pharmaceutical released its earnings data on Wednesday. The company reported EPS for the quarter, beating the Thomson Reuters consensus estimate of by $0.18, AR Network reports.
2 hrs ago
BioMarin Pharmaceutical Inc. Announces Second Quarter 2014 Financial Results
BioMarin Pharmaceutical Inc. today announced financial results for the second quarter ended June 30, 2014.
BioMarin Pharmaceutical Inc. To Host Second Quarter 2014 Financial...
BioMarin Pharmaceutical Inc. , a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, July 30, at 4:30 p.m. ET to discuss second quarter 2014 financial results and provide a ... (more)
BioMarin Pharmaceutical Sees Unusually Large Options Volume
Shares of BioMarin Pharmaceutical saw unusually large options trading on Monday.
BioMarin Pharmaceutical Inc. Announces Health Canada Approval Of...
The approval makes VIMIZIM the first and only pharmaceutical treatment option available in "Morquio A is an ultra-rare disease for which there is no cure.
Insider Selling: BioMarin Pharmaceutical CFO Sells 2,229 Shares of Stock
BioMarin Pharmaceutical CFO Daniel K. Spiegelman sold 2,229 shares of the stock in a transaction dated Wednesday, July 2nd.